BeyondSpring Inc.

BeyondSpring Inc., a clinical-stage biopharmaceutical company, reported a net loss of $14.2 million for the fiscal year ended December 31, 2025. The loss before income tax from continuing operations was $8.6 million, with an income tax expense of $90 thousand. Total assets decreased to $25.9 million, including $7.8 million in cash and cash equivalents, $4.8 million in short-term investments, and $20.9 million in total current assets. Total liabilities stood at $49.9 million, driven by $28.6 million in deferred revenue and discontinued operations liabilities, resulting in a total shareholders' deficit of $24.0 million. Cash flows reflected heavy R&D investment, with net cash used in operating activities of $19.8 million, partially offset by $10.8 million provided by investing activities, mainly $7.4 million from the sale of subsidiary interests and $18.4 million from short-term investment maturities, and $5.0 million from financing activities including $2.0 million from ordinary share issuance. Net decrease in cash was $3.9 million. The company continues development of Plinabulin and its pipeline, with no revenue reported, emphasizing liquidity management amid ongoing clinical trials and discontinued operations.

Key Takeaways